581809-67-8
Chemical Structure
A-425619
- CAS No.: 581809-67-8
- Formula:C18H14F3N3O
- Molecular Weight:345.32
IUPAC Name: 1-(isoquinolin-5-yl)-3-(4-(trifluoromethyl)benzyl)urea
InChIKey: SJGVXVZUSQLLJB-UHFFFAOYSA-N
SMILES: FC(F)(F)C(C=C1)=CC=C1CNC(NC2=CC=CC3=C2C=CN=C3)=O
Biological Activity: A-425619 is an orally active and selective transient receptor potential type V1 (TRPV1) antagonist. A-425619 blocks Capsaicin (HY-10448)- and N-arachidonoyl-dopamine (NADA)-induced Ca2+ influx in dorsal root ganglia and trigeminal ganglia. A-425619 relieves pathophysiological pain associated with inflammation and tissue injury in rats. A-425619 can be used for the study of pain related to inflammation and tissue injury[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
A-425619 | 99.96% | A-425619 is an orally active and selective transient receptor potential type V1 (TRPV1) antagonist. A-425619 blocks Capsaicin (HY-10448)- and N-arachidonoyl-dopamine (NADA)-induced Ca2+ influx in dorsal root ganglia and trigeminal ganglia. A-425619 relieves pathophysiological pain associated with inflammation and tissue injury in rats. A-425619 can be used for the study of pain related to inflammation and tissue injury. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. McDonald HA, et al. Characterization of A-425619 at native TRPV1 receptors: a comparison between dorsal root ganglia and trigeminal ganglia. Eur J Pharmacol. 2008 Oct 31;596(1-3):62-9. [Content Brief]
- [2]. El Kouhen R, et al. A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel and selective transient receptor potential type V1 receptor antagonist, blocks channel activation by vanilloids, heat, and acid. J Pharmacol Exp Ther. 2005 Jul;314(1):400-9. [Content Brief]
- [3]. Honore P, et al. A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats. J Pharmacol Exp Ther. 2005 Jul;314(1):410-21. [Content Brief]
